Links between Pharmaceutical R&D Models and Access to Affordable Medicines
Each patient in the European Union has a right of access to care. National governments face the challenge to balance resources against healthcare demand to ensure that populations enjoy equitable access to effective, affordable and sustainable healthcare. This study describes the main challenges with regard to access to affordable medicines, including Research & Development, pricing and reimbursement of medicines and the influence of the economic crisis. Potential policy options to tackle these challenges are presented, drawing on best practices and a review of specific measures implemented in different European countries. This document was provided by Policy Department A for the Committee on the Environment, Public Health and Food Safety.
Study
External author
Brian GODMAN, Wija OORTWIJN, Chiara DE WAURE, Ilaria MOSCA, Anna PUGGINA, Maria Lucia SPECCHIA, Paolo CAMPANELLA and Jeroen VAN DER TUIN
About this document
Publication type
Policy area
Keyword
- consumer price
- demography and population
- economic analysis
- ECONOMICS
- EU statistics
- European construction
- EUROPEAN UNION
- FINANCE
- health
- health costs
- medicine
- pharmaceutical expenses
- pharmaceutical legislation
- population ageing
- prices
- pricing of medicines
- PRODUCTION, TECHNOLOGY AND RESEARCH
- research and development
- research and intellectual property
- single market
- SOCIAL QUESTIONS
- supply
- trade
- TRADE